BMY:NYE-Bristol-Myers Squibb Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 49.74

Change

+0.25 (+0.51)%

Market Cap

USD 100.84B

Volume

7.77M

Analyst Target

USD 73.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. Address: Route 206 & Province Line Road, Princeton, NJ, United States, 08543

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
LLY Eli Lilly and Company

-1.21 (-0.13%)

USD 815.95B
JNJ Johnson & Johnson

-0.92 (-0.55%)

USD 402.18B
ABBV AbbVie Inc

-0.51 (-0.26%)

USD 341.70B
PFE Pfizer Inc

-0.08 (-0.27%)

USD 165.86B
OGN Organon & Co

-0.58 (-2.82%)

USD 5.20B
GSK GlaxoSmithKline PLC ADR

-0.13 (-0.31%)

N/A
MRK Merck & Company Inc

+0.35 (+0.30%)

N/A
NVS Novartis AG ADR

+0.27 (+0.23%)

N/A

ETFs Containing BMY

FHI:CA CI Health Care Giants Cov.. 5.55 % 0.75 %

-0.09 (0%)

CAD 0.07B
FHI-B:CA CI Health Care Giants Cov.. 5.55 % 0.00 %

N/A

CAD 0.05B
PPH VanEck Pharmaceutical ETF 4.89 % 0.36 %

-0.09 (0%)

USD 0.73B
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.55 % 0.00 %

-0.22 (0%)

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.49 % 0.00 %

-0.26 (0%)

N/A
KNGU:CA Brompton U.S. Cash Flow K.. 4.49 % 0.00 %

+0.15 (+0%)

CAD 4.92M
MEDX Horizon Kinetics Medical .. 4.15 % 0.00 %

+0.03 (+0%)

N/A
LSAT Two Roads Shared Trust - .. 3.71 % 0.00 %

+0.04 (+0%)

USD 0.12B
USMV:LSE Ossiam US Minimum Varianc.. 3.00 % 0.00 %

-1.95 (0%)

USD 0.01B
MVUS:PA 3.00 % 0.00 %

N/A

N/A
SPMV:PA 3.00 % 0.00 %

N/A

N/A
OSX2:XETRA Ossiam US Minimum Varianc.. 3.00 % 0.00 %

-1.80 (0%)

USD 0.12B
CDNA:CA 2.95 % 0.00 %

N/A

N/A
HEAL:CA 2.66 % 0.00 %

N/A

N/A
XDGI:XETRA Xtrackers MSCI Global SDG.. 2.65 % 0.00 %

-0.26 (0%)

USD 0.02B
PEY Invesco High Yield Equity.. 2.65 % 0.53 %

+0.01 (+0%)

USD 1.23B
WTD9:XETRA WisdomTree Issuer ICAV - .. 2.63 % 0.00 %

-0.11 (0%)

USD 0.05B
WTDY:XETRA WisdomTree Issuer ICAV - .. 2.63 % 0.00 %

-0.10 (0%)

USD 0.85M
WTEU:XETRA WisdomTree US Equity Inco.. 2.63 % 0.00 %

-0.09 (0%)

USD 0.11B
HDLV:XETRA Invesco S&P 500 High Divi.. 2.56 % 0.00 %

-0.12 (0%)

USD 0.31B
HDCH:SW Invesco S&P 500 High Divi.. 2.56 % 0.00 %

-0.17 (0%)

USD 3.51M
WTD9:F WisdomTree US Equity Inco.. 2.56 % 0.00 %

+0.29 (+0%)

USD 0.06B
WTDY:F WisdomTree Issuer ICAV - .. 2.56 % 0.00 %

+0.07 (+0%)

USD 1.79M
WTEU:F WisdomTree US Equity Inco.. 2.56 % 0.00 %

N/A

USD 0.11B
ZYUS:AU ANZ S&P 500 High Yield Lo.. 2.56 % 0.00 %

-0.07 (0%)

USD 0.07B
VSDA VictoryShares Dividend Ac.. 2.43 % 0.35 %

-0.11 (0%)

USD 0.26B
VDIV:XETRA VanEck Morningstar Develo.. 2.43 % 0.00 %

-0.03 (0%)

USD 0.64B
TDIV:SW VanEck Morningstar Develo.. 2.43 % 0.00 %

-0.05 (0%)

USD 0.94B
TDGB:LSE VanEck Morningstar Develo.. 2.39 % 0.00 %

-0.11 (0%)

USD 0.93B
DHS:SW WisdomTree US Equity Inco.. 2.39 % 0.00 %

N/A

N/A
DHSA:SW WisdomTree US Equity Inco.. 2.39 % 0.00 %

N/A

N/A
VDIV:F VanEck Vectors ETFs N.V... 2.36 % 0.00 %

+0.03 (+0%)

USD 0.64B
NXTV 2.35 % 0.00 %

N/A

N/A
LRND IQ U.S. Large Cap R&D Lea.. 2.31 % 0.00 %

-0.03 (0%)

USD 7.07M
TDOC:CA TD Global Healthcare Lead.. 2.24 % 0.00 %

+0.03 (+0%)

CAD 0.09B
RNDV First Trust US Equity Div.. 2.05 % 0.50 %

+0.02 (+0%)

USD 0.04B
SPDV AAM S&P 500 High Dividend.. 1.99 % 0.29 %

+0.10 (+0%)

USD 0.06B
PUD.B:CA 1.82 % 0.66 %

N/A

N/A
RSPH Invesco S&P 500® Equal.. 1.80 % 0.00 %

+0.01 (+0%)

USD 1.02B
UVDV 1.72 % 0.00 %

N/A

N/A
HEAL:SW iShares Healthcare Innova.. 1.65 % 0.00 %

-0.05 (0%)

N/A
ZLU-U:CA BMO Low Volatility US Equ.. 1.65 % 0.00 %

-0.35 (0%)

N/A
2B78:F iShares Healthcare Innova.. 1.61 % 0.00 %

-0.02 (0%)

N/A
JAVA JPMorgan Active Value ETF 1.54 % 0.00 %

-0.10 (0%)

USD 1.51B
EDGE:CA Evolve Innovation Index F.. 1.52 % 0.60 %

+0.07 (+0%)

CAD 0.04B
EDGE-U:CA Evolve Innovation Index F.. 1.52 % 0.00 %

N/A

N/A
UC82:LSE UBS(Lux)Fund Solutions .. 1.35 % 0.00 %

-1.00 (0%)

USD 0.07B
UC86:LSE UBS(Lux)Fund Solutions .. 1.35 % 0.00 %

-0.01 (0%)

USD 0.27B
SPXB 1.32 % 0.15 %

N/A

N/A
UC98:LSE UBS(Lux)Fund Solutions .. 0.74 % 0.00 %

-6.50 (0%)

USD 0.20B
BSUS:LSE UBS(Lux)Fund Solutions .. 0.72 % 0.00 %

-2.40 (0%)

N/A
UC97:LSE UBS(Lux)Fund Solutions .. 0.72 % 0.00 %

-0.04 (0%)

USD 0.20B
UET0:F UBS (Lux) Fund Solutions .. 0.65 % 0.00 %

-0.05 (0%)

N/A
UET0:XETRA UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

-0.03 (0%)

USD 0.21B
CBSUST:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

-0.03 (0%)

N/A
CBSUS:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

-0.07 (0%)

N/A
CBSUSE:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

N/A

N/A
CBSUSH:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

N/A

N/A
QUIG:CA Mackenzie US Investment G.. 0.62 % 0.28 %

N/A

CAD 0.55B
FUD:CA First Trust Value Line® .. 0.53 % 0.78 %

N/A

CAD 5.40M
UC76:LSE UBS Barclays US Liquid Co.. 0.53 % 0.00 %

-0.04 (0%)

USD 0.09B
UC85:LSE UBS Barclays US Liquid Co.. 0.53 % 0.00 %

-2.00 (0%)

USD 0.07B
DHS WisdomTree U.S. High Divi.. 0.00 % 0.38 %

-0.02 (0%)

N/A
GBF iShares Government/Credit.. 0.00 % 0.20 %

-0.34 (0%)

N/A
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

-0.02 (0%)

N/A
JHMH 0.00 % 0.46 %

N/A

N/A
ONEV SPDR® Russell 1000 Low V.. 0.00 % 0.20 %

-0.18 (0%)

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

+0.11 (+0%)

N/A
QLTA iShares Aaa - A Rated Cor.. 0.00 % 0.15 %

-0.16 (0%)

USD 1.42B
NUBD Nuveen ESG U.S. Aggregate.. 0.00 % 0.20 %

-0.09 (0%)

USD 0.41B
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

-0.05 (0%)

USD 0.02B
HONR 0.00 % 0.65 %

N/A

N/A
HUL-U:CA 0.00 % 0.00 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

-0.03 (0%)

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.03 (0%)

N/A
SCHD Schwab U.S. Dividend Equi.. 0.00 % 0.07 %

+0.05 (+0%)

USD 59.54B
SDOG ALPS Sector Dividend Dogs.. 0.00 % 0.40 %

N/A

USD 1.21B
SICK 0.00 % 0.95 %

N/A

N/A
SPHD Invesco S&P 500® High Di.. 0.00 % 0.30 %

-0.12 (0%)

USD 3.86B
UXM.B:CA 0.00 % 0.67 %

N/A

N/A
ZLU:CA BMO Low Volatility US Equ.. 0.00 % 0.33 %

-0.11 (0%)

CAD 1.74B
HUL:CA 0.00 % 2.20 %

N/A

N/A
BVAL 0.00 % 0.65 %

N/A

N/A
DHS:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

-12.10 (0%)

N/A
DHSA:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

-0.12 (0%)

N/A
DHSD:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

-0.07 (0%)

N/A
DHSG:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

-7.00 (0%)

N/A
DHSP:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

-14.25 (0%)

N/A
LUMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-225.00 (0%)

N/A
UC84:LSE UBS Barclays US Liquid Co.. 0.00 % 0.00 %

-6.50 (0%)

USD 0.09B
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.00 %

N/A

N/A
VMUS:XETRA 0.00 % 0.00 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A
HART IQ Healthy Hearts ETF 0.00 % 0.00 %

+0.05 (+0%)

USD 9.14M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.06% 11% F 21% F
Dividend Return 3.51% 67% D+ 66% D+
Total Return 0.45% 11% F 23% F
Trailing 12 Months  
Capital Gain -15.38% 11% F 12% F
Dividend Return 4.03% 78% C+ 57% F
Total Return -11.35% 11% F 13% F
Trailing 5 Years  
Capital Gain -1.64% 25% F 43% F
Dividend Return 20.59% 63% D 70% C-
Total Return 18.94% 25% F 45% F
Average Annual (5 Year Horizon)  
Capital Gain -2.62% 20% F 24% F
Dividend Return 0.57% 20% F 29% F
Total Return 3.19% 50% F 61% D-
Risk Return Profile  
Volatility (Standard Deviation) 19.12% 30% F 54% F
Risk Adjusted Return 3.00% 20% F 27% F
Market Capitalization 100.84B 33% F 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.